Literature DB >> 3052825

Neurochemical profile of tianeptine, a new antidepressant drug.

G Kato1, A F Weitsch.   

Abstract

Tianeptine is a new effective antidepressant drug. However, its neurochemical profile in animals differs from that of tricyclic or atypical antidepressants. In the present study, we compared the ex vivo effects of tianeptine on platelet serotonin uptake to those of clomipramine. Ex vivo, after subchronic (15 days, washout 24 h) treatment (10 mg/kg/day i.p.) in rats, tianeptine induced an increase (30%) in [14C]serotonin uptake at a [14C]serotonin concentration of 500 nM while clomipramine induced a decrease (40%) in [14C]serotonin uptake. Stimulation of uptake affected mainly Vmax but not Km. Tianeptine did not inhibit monoamine oxidase (MAO), MAOA or MAOB activity. In vitro, there was no binding of tianeptine to any of the various receptors examined: alpha- and beta-adrenergic, dopamine, serotonin, imipramine, GABA, glutamate, benzodiazepine, muscarinic, histamine, Ca2+ channels. After chronic administration (10 mg/kg/day for 15 days) tianeptine did not alter the concentration (Bmax) or the affinity (Kd) of alpha-2, beta-1, serotonin-1, serotonin-2, imipramine, benzodiazepine, or GABAB receptors. The major effect of tianeptine in rat platelets and synaptosomes is a small increase in 5-HT uptake after subchronic administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052825

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  24 in total

1.  Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function?

Authors:  Chay-Hoon Tan; Xin He; Jun Yang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2005-11-30       Impact factor: 1.972

2.  Discriminative stimulus properties of tianeptine.

Authors:  Tevfik Alici; Hakan Kayir; M Oguz Aygoren; Esra Saglam; I Tayfun Uzbay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

7.  Effect of prenatal exposure to tianeptine on different neurotransmitter receptors and 5-HT-stimulated inositol phosphate formation in rat brain.

Authors:  G Romero; E Toscano; D Montero; M C De Felipe; J Del Rio
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Tianeptine in combination with monoamine oxidase inhibitors for major depressive disorder.

Authors:  Edward H Tobe
Journal:  BMJ Case Rep       Date:  2012-10-09

9.  Tianeptine: an antidepressant with memory-protective properties.

Authors:  Phillip R Zoladz; Collin R Park; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.